The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2019 | Chromatin activation underlying pathogenic mechanisms in MM & CLL
Iñaki Martín-Subero, PhD, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, describes a recent publication looking at chromatin activation as the underlying principle in pathogenic mechanisms in multiple myeloma (MM) and chronic lymphocytic leukemia (CLL). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
